AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
12,604
-84 (-0.66%)
Jul 24, 2026, 10:49 AM GMT
Market Cap196.79B +22.6%
Revenue (ttm)45.77B +9.9%
Net Income7.87B +33.7%
EPS5.03 +33.6%
Shares Out 1.55B
PE Ratio25.23
Forward PE15.98
Dividend2.36 (1.86%)
Ex-Dividend DateFeb 19, 2026
Volume157,148
Open12,650
Previous Close12,688
Day's Range12,578 - 12,654
52-Week Range10,524 - 15,732
Beta0.22
AnalystsBuy
Price Target15,773.01 (+25.14%)
Earnings DateJul 27, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]

Sector Healthcare
Founded 1992
Employees 96,100
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Financial numbers in USD Financial Statements

Analyst Summary

According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,773p, which is an increase of 25.14% from the latest price.

Price Target
15,773p
(25.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca

The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants diges...

1 hour ago - Invezz

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and mai...

3 hours ago - Reuters

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised to con...

19 hours ago - PRNewsWire

AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cancer Treatment

AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cancer Treatment

21 hours ago - GuruFocus

AstraZeneca announces Etcamah with CDK4/6 inhibitor approved in EU

AstraZeneca’s (AZN) Etcamah in combination with a cyclin-dependent kinase, CDK, 4/6 inhibitor has been approved in the European Union, EU, for the treatment of adult patients with estrogen receptor-po...

23 hours ago - TheFly

AstraZeneca Secures EU Nod For Etcamah In Advanced Breast Cancer

(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib)...

1 day ago - Nasdaq

AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues

The approval opens a big market for camizestrant as U.S. regulators continue to review the company's application there.

1 day ago - WSJ

AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $AZN--AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm.

1 day ago - Business Wire

Hair loss with GLP-1 drugs is rare, but real, studies find

The risk ‌of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.

1 day ago - Reuters

Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront

Royalty Pharma (RPRX) announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s (AZN) cliramitug for up to $425M, including $125M upfront. Cliramitug is a Phase 3…

1 day ago - TheFly

Royalty Pharma Acquires Neurimmune's Royalty Interest In AstraZeneca's Cliramitug For $425 Mln

(RTTNews) - Wednesday, Royalty Pharma plc (RPRX) announced the acquisition of Neurimmune's royalty interest in AstraZeneca's (AZN) cliramitug for up to $425 million.

1 day ago - Nasdaq

AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regulations

AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regulations

2 days ago - GuruFocus

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN).  Such investors are advised to...

2 days ago - GlobeNewsWire

Abivax re-engages Centerview amid renewed takeover interest, La Lettre says

Marc de Garidel’s company suspended takeover talks with pharma giants including AstraZeneca (AZN) and Eli Lilly (LLY) last month as it secured an EUR 800M capital raise. Its new funding…

6 days ago - TheFly

AstraZeneca price target lowered to 15,300 GBp at Morgan Stanley

Morgan Stanley lowered the firm’s price target on AstraZeneca (AZN) to 15,300 GBp from 16,500 GBp and keeps an Overweight rating on the shares.

7 days ago - TheFly

AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky

AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.

7 days ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised to con...

7 days ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN).  Such investors are advised to...

9 days ago - GlobeNewsWire

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform tria...

9 days ago - GlobeNewsWire

AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)

AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)

9 days ago - GuruFocus

AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition

AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition

9 days ago - GuruFocus

AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M

Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca (AZN) for Zegfrovy, an oral irreversible epidermal growth factor receptor, or EGFR, inhibitor for patient...

10 days ago - TheFly

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.

10 days ago - WSJ

AstraZeneca Enters Global License Agreement For Zegfrovy

LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy, an oral irreversible epidermal growth f...

10 days ago - Finanz Nachrichten

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one ​of its drugs for a type of ‌lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange ...

10 days ago - Reuters